Clinical Trials Logo

Fibrinolysis; Hemorrhage clinical trials

View clinical trials related to Fibrinolysis; Hemorrhage.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03897621 Completed - Clinical trials for Total Hip Arthroplasty

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery

Start date: May 20, 2019
Phase: N/A
Study type: Interventional

Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot resolution. TXA is employed currently based on a surgeon's preference. The objective of this study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM) and investigate the role of TXA prophylaxis on blood loss in patients undergoing THA in a double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA prophylaxis is not necessary during THA. All patients, whether they receive TXA or normal saline, will not be at risk, as at this time no data exists to determine which approach is safer or more effective. This is the first study to compare TXA vs. placebo in a double-blinded, randomized controlled trial.

NCT ID: NCT03856164 Completed - Blood Loss Clinical Trials

Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery

TXA
Start date: June 17, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators prepared a novel study of tranexamic acid (TXA) designed to estimate the quantity of blood loss in women undergoing elective repeat cesarean deliveries. This is the first trial to utilize a prophylactic dose of TXA prior to incision followed by a subsequent prophylactic dose at placental delivery in obstetric patients undergoing scheduled cesareans. The purpose of this study is to quantify blood loss during uncomplicated repeat cesarean deliveries with and without TXA. The central hypothesis is that TXA administration reduces blood loss and fibrinolysis in women undergoing repeat cesarean sections.